A Phase 2 interventional study of filgotinib and Placebo Oral Tablet in Ankylosing Spondylitis, sponsored by Galapagos NV. Completed at 30 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-13.
Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Spondylitis, Ankylosing with a site in Ukraine — none open to participants now, none under way, none of them phase 3. Spondylitis, Ankylosing · Ukraine.
Among the 11 studies in Spondylitis, Ankylosing with a site in Ukraine, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2017, is one of 4 in phase 2, and was the 7th registered.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.
Browse Spondylitis, Ankylosing studies →None of the 11 studies in Spondylitis, Ankylosing with a site in Ukraine is open now. The open studies under Spondylitis, Ankylosing, anywhere →
Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 116 is above the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Median enrollment 263 across the 10 interventional studies, 809 across the 1 observational. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 8 most frequent:
This study is registered under Galapagos NV, one of the names counted as Lakefront Biotherapeutics NV. Under that name alone:
Galapagos NV is the lead sponsor of 103 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.
Lakefront Biotherapeutics NV has 2 studies filed under Spondylitis, Ankylosing — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Spondylitis, Ankylosing with a site in Ukraine, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, Phase 2, double-blind, placebo-controlled study in subjects with active Ankylosing Spondylitis (AS). A total of approximately 100 subjects will be randomized to one of 2 treatment arms in a 1:1 ratio: oral filgotinib tablets q.d. or matching placebo q.d. Treatment duration will be 12 weeks. Each subject will stay in the study for a maximum of 20 weeks (from Screening visit to Follow-up visit).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: filgotinib
Drug: Placebo Oral Tablet
one filgotinib oral tablet q.d.
one placebo oral tablet q.d.
Ankylosing Spondylitis disease activity score (ASDAS) in filgotinib treated subjects as compared to placebo
To evaluate the effect of filgotinib on the AS disease activity score
Time frame: week 12
Assessment of SpondyloArthritis international Society (ASAS) in filgotinib treated subjects as compared to placebo
To evaluation the effect of filgotinib on the ASAS score in AS patients
Time frame: week 12
Assessment by a trained joint assessor of 44 joints for tenderness (counting the number or tender joints - TJC) and swelling (counting the number of swollen joints - SJC) in filgotinib treated subjects as compared to placebo
To evaluate the effect of filgotinib on joint tenderness and swelling in AS patient
Time frame: week 12
Assessement of the Bath Ankylosing Spondylitis Disease Activity Index in filgotinib treated subjects as compared to placebo
To assess the effect of filgotinib on BAS disease activity index in AS patients
Time frame: week 12
Assessment of the Bath Ankylosing Spondylitis Functional Index in filgotinib treated subjects as compared to placebo
To assess the effect of filgotinib on BAS functional index in AS patients
Time frame: week 12
Assessment of the Bath Ankylosing Spondylitis Metrology Index in filgotinib treated subjects as compared to placebo
To assess the effect of filgotinib on BAS metrology index in AS patients
Time frame: week 12
Assessment Spondyloarthritis Research Consortium of Canada MRI in filgotinib treated subjects as compared to placebo
To assess the effect of filogtinib on Spondyloarthritis Research Consortium of Canada MRI in AS patients
Time frame: week 12
Assessment of the Maastricht Ankylosing Spondylitis Enthesitis Score in filgotinib treated subjects as compared to placebo
To assess the effect of filgotinibe on Maastricht Ankylosing Spondylitis Enthesitis Score in AS patients
Time frame: week 12
Assessment of FACIT fatigue scale in filgotinib treated subjects as compared to placebo
To assess the effect of filgotinib on FACIT fatigue scale in AS patients
Time frame: week 12
Assessment of SF-36 health survey in filgotinib treated subjects as compared to placebo
To assess the effect of filgotinib on SF-36 health survey in AS patients
Time frame: week 12
Assessment of Ankylosing Spondylitis Quality of Life questionnaire (ASQoL) in filgotinib treated subjects as compared to placebo
To assess the effect of filgotinib on ASQoL in AS patients
Time frame: week 12
Difference between filgotinib treated subjects and placebo subjects in the number of Adverse events
To assess safety and tolerability of filgotinib in AS patients
Time frame: from baseline until the final follow up visit (week 16)
Difference in the number of filgotinib subjects and placebo subjects with abnormal Clinical laboratory evaluations
To assess safety and tolerability of filgotinib in AS patients
Time frame: from baseline until the final follow up visit (week 16)
Difference in the number of filgotinib treated subjects and placebo subjects with abnormal vital signs
To assess safety and tolerability of filgotinib in AS patients
Time frame: from baseline until the final follow up visit (week 16)
Difference between the number of filgotinib treated subjects and placebo subjects with abnormal physical examination
To assess safety and tolerability of filgotinib in AS patients
Time frame: from baseline until the final follow up visit (week 16)
Difference between the number of filgotinib treated subjects and placebo with abnormal ECG
To assess safety and tolerability of filgotinib in AS patients
Time frame: At baseline, end of study visit (week 12) and final follow up visit (week 16)
Difference between the number of filgotinib treated subjects and placebo with abnormal radiographic assessment
To assess safety and tolerability of filgotinib in AS patients
Time frame: At baseline and end of study visit (week 12)
Plan to share: Undecided
Ran from Mar 2017 to primary completion in Jul 2018, 15 months.
Of 22 phase 2 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 15 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG0634